Sanofi Genzyme

Primary tabs

Sanofi Genzyme

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. 

Content from this campaign

Plan Bee: Combating the Declining Bee Population
A troubling trend has been preoccupying scientists: Honey bees are disappearing or dying at increasing rates. Last year alone, 44% of the bee colonies in the United States disappeared. While no exact cause has been determined, scientists have termed the issue Colony Collapse Disorder (CCD), a phenomenon in which very low or no adult honey bees are present in formerly active hives, leaving...
Sep 5, 2016 10:10 AM ET
Genzyme’s Biologics Support Center Achieves LEED Gold Rating for Environmentally Responsible Design
(3BL Media) Cambridge, MA - May 14, 2012 - Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced that its...
May 14, 2012 12:00 PM ET
Genzyme’s Multiple Sclerosis Team Ready to “Rock” and Roll!
(3BL Media) March 20, 2012 - As Genzyme prepares to launch our new Multiple Sclerosis (MS) business unit, the global MS medical team gathered for a three-day summit in Cambridge, Mass. at the end of February. The participants included 120 MS medical directors, managers, and Medical Science Liaisons (MSLs) as well as members from other MS teams, such as market access, risk management,...
Mar 20, 2012 7:00 PM ET